Estrogen protects women from NAFLD before menopause by reducing the TG accumulation in the liver via the activation of the estrogen receptor (ER), which is the main receptor of E2, or the G protein-coupled estrogen receptor (GPER or Gpr30), a receptor of 2-ME2 [2]. Here, GPER1 is linked to metabolic dysfunction-associated steatotic liver disease.